Abstract | BACKGROUND: OBJECTIVES: To provide a meta-analysis evidence-based examination of IVIg efficacy against TEN. METHODS: A systematic review and meta-analysis of literature published before 31 July 2011 was conducted. In observational controlled studies with at least eight patients with TEN receiving IVIg treatment, a pooled estimate of mortality risk was determined, comparing IVIg and supportive care. Statistical analyses were performed on raw data to compare the clinical differences between (i) high-dose and low-dose IVIg treatment in adult patients and (ii) paediatric and adult patients treated with IVIg. RESULTS: Seventeen studies met inclusion criteria. Overall mortality rate of patients with TEN treated with IVIg was 19.9%. The pooled odds ratio (OR) for mortality from six observational controlled studies comparing IVIg and supportive care was 1.00 [95% confidence interval (CI) 0.58-1.75; P=0.99]. The pooled OR for mortality in patients treated with high-dose IVIg vs. supportive care was 0.63 (95% CI 0.27-1.44; P=0.27). Adults treated with high-dose IVIg exhibited significantly lower mortality than those treated with low-dose IVIg (18.9% vs. 50%, respectively; P=0.022); however, multivariate logistic regression model adjustment indicated that IVIg dose does not correlate with mortality (high vs. low dose: OR 0.494; 95% CI 0.106-2.300; P=0.369). Paediatric patients treated with IVIg had significantly lower mortality than adults (0% vs. 21.6%; P=0.001). CONCLUSIONS: Although high-dose IVIg exhibited a trend towards improved mortality and children treated with IVIg had a good prognosis, the evidence does not support a clinical benefit of IVIg. Randomized controlled trials are necessary.
|
Authors | Y-C Huang, Y-C Li, T-J Chen |
Journal | The British journal of dermatology
(Br J Dermatol)
Vol. 167
Issue 2
Pg. 424-32
(Aug 2012)
ISSN: 1365-2133 [Electronic] England |
PMID | 22458671
(Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
|
Copyright | © 2012 The Authors. BJD © 2012 British Association of Dermatologists. |
Chemical References |
- Immunoglobulins, Intravenous
|
Topics |
- Adolescent
- Adult
- Aged
- Child
- Epidemiologic Methods
- Humans
- Immunoglobulins, Intravenous
(therapeutic use)
- Length of Stay
- Middle Aged
- Stevens-Johnson Syndrome
(drug therapy)
- Treatment Outcome
- Young Adult
|